Originally developed for diabetes, they have also come to the fore for their effects against obesity. However, the Science article also highlights concerns about costs, availability, side effects and the potential need to be employed on a permanent basis
The American scientific journal Science called the development of peptide-1 (GLP-1) agonists the breakthrough of this year. Originally developed for diabetes almost 20 years ago, the enthusiasm around GLP-1 drugs to treat obesity exploded this year thanks also to the statements of some American personalities with Elon Musk and others from the star system who said they used them . This year, there were two studies that showed that GLP-1 agonists produced health benefits that go beyond weight loss itself. Furthermore, several studies are currently underway on their use in the treatment of drug addiction, Alzheimer's disease and Parkinson's disease. But despite all their promises, GLP-1 agonists raised more questions than they answered—a hallmark of a true breakthrough wrote Science magazine editor Holden Thorp in a related editorial. Both the dedicated article and its accompanying editorial highlight how the development and implementation of these drugs is forcing important conversations about how obesity is viewed, which could help reduce stigma and judgment about weight. However, the article also highlights concerns about the drugs' cost, availability, associated side effects and their potential need to be taken indefinitely. Doctors also worry that people who are not obese or overweight are resorting to using them to lose weight quickly.
As effective as these drugs are, however, they can also have significant side effects, such as nausea and vomiting, stomach pain and, more rarely, gastric paralysis, pancreatitis and intestinal obstructions. In some clinical trials, approximately 1 in 5 patients who started treatment failed to make it to the end of the study. It remains unclear whether these drugs pose a lifelong commitment for people who want to maintain their weight loss.
Another aspect to consider: i poison control centers in the United States say they have seen a sharp increase in calls related toabuse of these drugs. America's Poison Centers, CNN reportsreported a more than 15-fold increase compared to 2019. In 94% of calls, this drug was the only substance reported.
Semaglutide for weight loss: the (risky) trend born on social media, what we know about the antidiabetic used to lose weight
The drug of Hollywood stars
Corriere della Sera also on Whatsapp. sufficient click here to subscribe to the channel and always be updated.
December 15, 2023 (modified December 15, 2023 | 10:34)
© ALL RIGHTS RESERVED
#Semaglutide #antidiabetic #lose #weight #discovery #year #Science